CIC:	Hospital UPN:	Patient UIC	 HSCT Date:	
				yyyy - mm - dd

HSCT - Minimum Essential Data - A

SECOND REPORT - 100 DAYS AFTER HSCT

Disease				
PRIMARY DISEASE DIAGNOSIS				
Centre Identification				
EBMT Code (CIC): Contact person:				
Hospital: Unit: Email:				
Patient Data				
Date of this report:				
Hospital Unique Patient Number/ Code: (Compulsory, registrations will not be accepted without this item) (First name(s), family name(s))				
Initials: (first name(s) _family name(s)) Date of birth Sex Male Female yyyy - mm - dd (at birth)				
Date of the transplant: yyyy - mm - dd				
Recovery				
Absolute neutrophil count (ANC) recovery (Neutrophils ≥ 0.5 x 10 °/L; first of 3 consecutive values after 7 days without any transfusion containing neutrophils) No: Date of last assessment: yyyy - mm - dd Yes: Date of ANC recovery: yyyy - mm - dd Never below Unknown				
Platelet reconstitution (Platelets ≥ 20 x 10 ⁹ /L; first of 3 consecutive values after 7 days without transfusion) No Yes: Date Platelets ≥ 20 x 10 ⁹ /l Never below this level Date unknown: patient discharged before levels reached Date unknown: out-patient Unknown Early graft loss (Engraftment followed by loss of graft within the first 100 days)				
No Yes				

CIC:	Но	spital UPN:	Patient UIC	HSCT Date:			
				уууу - тт - аа			
Acute GvHD (Allografts)							
Acute (Graft Versus Host Di	sease (Allografts only)					
Maximu	m Grade:						
	0 (none) 🔲 I		IV \square Present but grade unknown	\square Not evaluated			
Date of	onset	- dd					
Stage:							
	Skin	' '	□ 1 □ 2 □ 3	□ 4			
	Liver		☐ 1 ☐ 2 ☐ 3	☐ 4			
	Lower GI tract	_ ` ′	☐ 1 ☐ 2 ☐ 3	□ 4			
	Upper GI tract		」 1				
	Other site affected	☐ No	Yes				
		Additio	onal Cell Infusions				
Additio	onal cell infusions	(excluding a new HSCT)					
□ No							
Yes:	lc +l	his call infusion an allogana	is boost? No Ves	Skin Call tharany table balow			
	☐ Yes: ☐ Is this cell infusion an allogeneic boost? ☐ No ☐ Yes: - Skip Cell therapy table below An allo boost is an infusion of cells from the same donor without conditioning, with no evidence of graft rejection.						
	Is th	nis cell infusion an autologo	us boost?	Skip Cell therapy table below			
		<u>not</u> a boost fill in the Cel	_	, , , , ,			
	Cell therapy	<u></u>	. therapy				
	First date of the c	ell therapy infusion	yyy - mm - dd				
		_					
	Source of cell(s): (check all that apply	∟ Allo □ Au ⁄)	to				
	Type of cell(s): (c	heck all that apply)					
	Lymphoc	yte (DLI) \square Mesenchym	nal \square Fibroblasts \square \square	Dendritic cells			
	\square NK cells	Regulatory T	-cells \Box Gamma/delta cells \Box C	Other, specify			
Chronological number of the cell infusion episode for this patient Indication: (check all that apply)							
							<u></u>
	☐ Planned/proto	col	☐ Treatment for disease				
	Prophylactic	SALID	Mixed chimaerism				
	☐ Treatment of G		Treatment viral infection				
	Loss/decreased						
	Treatment PTLD, EBV lymphomaOther, specify:						
	Utner, specify:						
	Number of infusion	ons within 10 weeks					
	(count only infusions that are part of same regimen and given for the same indication)						

CIC:	Hospital UPN:	Patient	UIC	HSCT Date:	yyyy - mm - dd		
		Additional Disea	se Treatment		7777		
Additional disease tre	atment given (ex	cluding cell infusion)					
☐ No							
Yes: Reason for this	s additional treatmen	t					
		nned before the transpl	ant took place)				
•	e / progression or per	sistent disease (not p	olanned)				
Date started	yyy - mm - dd						
Chemo/o							
☐ No							
☐ Yes:	☐ Imatinib mes	late (Gleevec, Glivec)					
	Dasatinib (Sp	ycel)					
	Nilotinib (Tas						
	Bortezomib (
	Lenalidomide	tuxan, mabthera)					
	☐ Velafermin (F						
		GF, palifermin)					
	Thalidomide						
	Eculizumab (S						
		_	Intrathecal:	□ No □ Y	Yes		
Radiotherapy	□ No	o ∐ Yes	Unknown				
		Best res	ponse				
Best disease status (esponse) after HSC	Т					
(prior to any treatment This field is <u>not mandato</u>	· · · · · · · · · · · · · · · · · · ·	·	ise assessment)				
Continued complete	remission (CCR)						
CR achieved: Date							
yyyy - mm - dd ☐ Never in CR: Date assessed:							
Not evaluated		yy - mm - dd					
Last Contact Date for 100 day Assessment							
If patient has died before	this date, enter date	of death, otherwise ent	er Date of HSCT + 100 DA	AYS APPROX.			
Day 100 asse	ssment :	mm - dd					
D-4f d4l		mm - dd					
Date of death (if before day 100):							
Chronic GvHD at day 100 (Allografts)							
Chronic Graft Versus Host Disease present between HSCT and 100 days or date of death							
(allografts only)							
☐ No <i>(never)</i>							
☐ Yes: Date of diagnosis of cGvHD							
yyyy - mm - dd Maximum extent <u>during this period</u>							
Maximum extent <u>during this period</u> ☐ Limited ☐ Extensive ☐ Unknown							
	Maximum NIH score <u>during this period</u>						
		Severe	calculated				
IVIIIQ	ouclute	_ NOT	carculated				

CIC:	Hospita	Il UPN:	Patient UIC	HSCT Date:				
		Relap	se/Progression	yyyy mm dd				
First Relapse or Progression after HSCT (detected by any method								
☐ No:								
Yes:	Yes: Date first seen yyyy - mm - dd							
☐ Contin	nuous progression since	HSCT						
		Relapse	e of Leukaemias					
	If Yes or Continuous <u>and</u> diagnosis is acute or chronic leukaemia, fill in the section below:							
	Method of detection of the first relapse or progression after HSCT Fill in only for acute and chronic leukaemias Relapse/progression detected by clinical/haematological method:							
	□ No: Da	te assessed						
	☐ Yes: Da	te first seen	dd					
	yyyy - mm - dd Not evaluated							
	Relapse/progression detected by cytogenetic method:							
	□ No: Da	te assessed						
	☐ Yes: _{Da}	te first seen	уууу - mm - dd					
	\square Not evaluated							
	Relapse/progression de	etected by <u>molecular</u> meth	od:					
	□ No: Da	te assessed						
	☐ Yes: _{Da}	te first seen	уууу - mm - dd					
	☐ Not evaluated							
Disease assessment at 100 days (All diseases)								
Disease status when the patient was last seen before day 100 or date of death (record the most recent status and date for each method, depending on the disease)								
Was disease detected by clinical/haematological method when the patient was last assessed before day 100 or date of death?								
□ No □ Yes								
Last date assessed								
☐ Not evaluated since HSCT was done								

CIC:	Hospital UPN:	Patient UIC		HSCT Date:	yyyy - mm - dd
	Disease A	Assessment at 100			
	l by <u>cytogenetic/FISH</u> meth nd chronic leukaemias	nod when the patient was l	ist assessed before day	100 or date	of death?
☐ No ☐ Yes: W	/as the presence of the dis-	ease considered relapse/pr	ogression since HSCT?	☐ No	Yes:
Last date assesse	ed yyyy - mm - dd				
Not evaluated sin	ce HSCT was done				
	l by <u>molecular</u> method wh nd chroni leukaemias	nen the patient was last ass	essed before day 100 or	date of dea	th?
☐ No ☐ Yes: W	/as the presence of the dis-	ease considered relapse/pr	ogression since HSCT?	☐ No	Yes:
Last date assesse	yyyy - mm - dd				
☐ Not evaluated sin	ce HSCT was done				
	Surviva	al Status at 100 day	's – All diseases		
☐ Relaps ☐ Second ☐ HSCT I ☐ Unknot ☐ Other_	ontributory Cause of Deat GVHD Interstitial pneumonitis Pulmonary toxicity Infection: bacterial		oriate):		
	viral Fungal parasitic Unknown Rejection/Poor graft funct History of severe Veno occ Haemorrhage Cardiac toxicity Central nervous system (Cl Gastrointestinal (GI) toxicit Skin toxicity Renal failure Multiple organ failure Other, specify	clusive disorder (VOD) NS) toxicity ty			